Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
Upcoming Financial Results Call: Acurx Pharmaceuticals will discuss its Q3 2025 financial results on November 12, 2025, at 8:00 am ET, hosted by CEO David P. Luci and CFO Robert G. Shawah.
Ibezapolstat Development: The company's lead antibiotic candidate, ibezapolstat, is preparing for international Phase 3 clinical trials to treat C. difficile infections, having received positive regulatory guidance from the EMA.
Regulatory Designations: Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) and received "Fast Track" designation from the FDA, highlighting its potential in addressing urgent bacterial threats.
Company Focus: Acurx Pharmaceuticals specializes in developing a new class of antibiotics targeting difficult-to-treat bacterial infections, particularly those caused by Gram-positive bacteria.
Trade with 70% Backtested Accuracy
Analyst Views on ACXP
About ACXP
About the author
"New to The Street Celebrates Milestone Episode #700 Airing Today at 6:30 PM ET on Bloomberg Television"
New to The Street Milestone: The business television platform "New to The Street" celebrated its 700th episode, airing on Bloomberg Television, highlighting its growth in various media channels and showcasing innovative companies in technology, finance, healthcare, and consumer culture.
Featured Companies: The episode featured several companies, including Lionscrest Advisors, DataVault AI, Pudgy Penguins, Peer To Peer Network, and Acurx Pharmaceuticals, each recognized for their contributions to their respective industries.
Lionscrest Advisors: This global advisory firm specializes in capital markets, M&A, and corporate finance, providing strategic insights to clients navigating complex financial landscapes.
DataVault AI and Others: DataVault AI focuses on AI-driven business intelligence and data management, while Pudgy Penguins has expanded into mainstream media and retail, and Acurx Pharmaceuticals is developing new antibiotics for challenging bacterial infections.
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Financial Compliance and Stock Split: Acurx Pharmaceuticals executed a 1-for-20 reverse stock split, regaining compliance with Nasdaq's minimum bid price and stockholders' equity requirements, ensuring continued listing on the Nasdaq Stock Market.
Patent Developments: The company received a new patent from the Australian Patent Office for its DNA polymerase IIIC inhibitors, adding to its existing patents in the U.S. and other countries, which cover treatments for infections caused by Gram-positive bacteria.
Research and Development Updates: Acurx presented at IDWeek 2025, showcasing new data on its lead antibiotic candidate, ibezapolstat, which is preparing for Phase 3 clinical trials to treat C. difficile infections, and published significant findings in Nature Communications regarding its mechanism of action.
Financial Performance: Acurx reported a net loss of $2.0 million for Q3 2025, an improvement from the previous year's loss, with cash reserves increasing to $5.9 million, supported by recent fundraising efforts through warrant exercises and an equity line of credit.
